Cencora, Inc. (NYSE:COR - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2026 earnings estimates for Cencora in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $17.08 per share for the year, up from their previous forecast of $16.44. The consensus estimate for Cencora's current full-year earnings is $14.93 per share.
Several other equities research analysts have also recently commented on COR. Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a report on Thursday. Barclays lifted their price target on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Finally, Bank of America restated a "neutral" rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $271.20.
Get Our Latest Research Report on COR
Cencora Price Performance
Cencora stock traded up $0.68 during trading hours on Monday, hitting $249.09. 1,232,651 shares of the company traded hands, compared to its average volume of 1,409,097. The firm's 50-day simple moving average is $231.95 and its two-hundred day simple moving average is $230.74. The firm has a market cap of $49.08 billion, a P/E ratio of 33.17, a P/E/G ratio of 1.61 and a beta of 0.44. Cencora has a 1-year low of $191.11 and a 1-year high of $251.52. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.
Cencora Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Friday, November 15th. Cencora's payout ratio is 27.16%.
Insider Activity at Cencora
In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.80% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Kingswood Wealth Advisors LLC acquired a new stake in Cencora in the 2nd quarter worth approximately $655,000. TD Asset Management Inc acquired a new stake in shares of Cencora in the first quarter worth $95,313,000. LSV Asset Management bought a new stake in shares of Cencora during the 1st quarter worth $3,579,000. Lake Street Advisors Group LLC acquired a new position in Cencora during the 1st quarter worth $836,000. Finally, Czech National Bank boosted its holdings in Cencora by 8.3% during the second quarter. Czech National Bank now owns 31,546 shares of the company's stock valued at $7,107,000 after acquiring an additional 2,414 shares during the period. Institutional investors own 97.52% of the company's stock.
About Cencora
(
Get Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
